{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Rivoceranib_Mesylate",
  "nciThesaurus": {
    "casRegistry": "1218779-75-9",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "The mesylate salt of rivoceranib, an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.",
    "fdaUniiCode": "TK02X14ASJ",
    "identifier": "C74012",
    "preferredName": "Rivoceranib Mesylate",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C1742",
      "C1967"
    ],
    "synonyms": [
      "Apatinib Mesylate",
      "RIVOCERANIB MESYLATE",
      "Rivoceranib Mesylate",
      "YN-968D1",
      "YN968D1"
    ]
  }
}